U.S. markets close in 6 hours 29 minutes
  • S&P 500

    4,167.85
    +0.26 (+0.01%)
     
  • Dow 30

    34,306.09
    +75.75 (+0.22%)
     
  • Nasdaq

    13,546.10
    -36.32 (-0.27%)
     
  • Russell 2000

    2,241.37
    -6.92 (-0.31%)
     
  • Crude Oil

    65.51
    -0.12 (-0.18%)
     
  • Gold

    1,792.00
    +7.70 (+0.43%)
     
  • Silver

    26.89
    +0.36 (+1.37%)
     
  • EUR/USD

    1.2057
    +0.0048 (+0.40%)
     
  • 10-Yr Bond

    1.5860
    +0.0020 (+0.13%)
     
  • GBP/USD

    1.3899
    -0.0009 (-0.06%)
     
  • USD/JPY

    109.3170
    +0.1280 (+0.12%)
     
  • BTC-USD

    57,395.16
    +1,491.41 (+2.67%)
     
  • CMC Crypto 200

    1,476.83
    +5.42 (+0.37%)
     
  • FTSE 100

    7,048.90
    +9.60 (+0.14%)
     
  • Nikkei 225

    29,331.37
    +518.77 (+1.80%)
     

Pharvaris to Participate in BioCapital Europe

  • Oops!
    Something went wrong.
    Please try again later.
Pharvaris N.V.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.

Participation Details:
Title: “Shaping the New Biotech Reality – Key Lessons from COVID” Panel Presentation
Date/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST)

Title: Pharvaris Corporate Presentation
Date/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST)

The virtual presentation will be available for 30 days on the Pharvaris website at https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.

Investor Contact
Chad Rubin, Solebury Trout
crubin@soleburytrout.com

Media Contact
Maggie Beller, Russo Partners, LLC
maggie.beller@russopartnersllc.com
+1-646-942-5631